Kyverna Therapeutics reported one-year results supporting its FDA submission pathway for an autoimmune CAR-T program in stiff person syndrome. The data add to the durability narrative for rare autoimmune disorders where long-term remission is the key clinical goal. The company’s updates come as regulators continue to evaluate whether rare-disease efficacy evidence, once established, can translate into durable benefit sufficient for filing and approval. For competitors and partners, the main takeaway is the emphasis on persistence of response and safety characterization over multiple time horizons, rather than short-term response alone.